Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 11/20 | 0.58 |
| ▸ | TPSD1 | Q9BZJ3 | 11/20 | 0.58 |
| ▸ | TPSG1 | Q9NRR2 | 11/20 | 0.58 |
| ▸ | ASAH1 | Q13510 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697345 | 1.00 | TPSAB1 (0.58) | TPSAB1TPSD1TPSG1ASAH1EPHX2 | |
| SCHEMBL3338948 | 0.88 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1ASAH1P2RX4 | |
| SCHEMBL4697644 | 0.86 | TPSAB1 (0.50) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL3335469 | 0.85 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL3332397 | 0.85 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL4697607 | 0.83 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1ASAH1P2RX4 | |
| SCHEMBL3333854 | 0.81 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1EPHX2 | |
| SCHEMBL3336687 | 0.81 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1EPHX2 | |
| SCHEMBL3333102 | 0.79 | TPSAB1 (0.53) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL3333866 | 0.79 | TPSAB1 (0.56) | TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871741-A2 | SUBSTITUTED AZETIDINONES | Daiamed, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |